Addiction

Papers
(The H4-Index of Addiction is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Issue Information221
Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling189
An Addiction series on regional perspectives on addiction‐related problems94
Society for the Study of Addiction Annual Conference 202494
90
89
Impulsivity behaviors and white matter mediate the relationship between genetic risk for cannabis use disorder and early cannabis use in adolescents85
Education matters: longitudinal pathways to mid‐life heavy drinking in a national cohort of black Americans85
Will Australia's tightened prescription system reduce nicotine vaping among young people?82
Commentary on Keyes and Patrick: Changes in psychedelic use in the United States may require changes in our narrative of psychedelic harms72
Commentary on Nower et al: The Pathways Model should apply to non‐clinical gambling patterns70
Significant changes in preference of illicit drug use in a population of Hanoi, Vietnam—A 6‐year wastewater study (2018–2023)70
Structure and stability of internet gaming disorder from childhood to late adolescence: A 5‐wave birth cohort study69
National profile on substance use, substance use‐related problems and policy: The case of Chile69
62
Estimating recent trends in alcohol sales in the United Kingdom from alcohol duty revenue58
Does recreational cannabis legalization change cannabis use patterns? Evidence from secondary school students in Uruguay55
Commentary on Lange et al.: Acute alcohol use before suicide—is it contributing to an increase in suicide rates in the United States?53
Recent decline in Chinese alcohol production and consumption: Potential contributing factors and the role of globally recommended measures52
The use of financial incentives for smoking cessation in pregnant women: A parallel‐group randomised controlled trial protocol52
Chronic obstructive pulmonary disease in heroin users: An underappreciated issue with clinical ramifications50
Use of cessation products, e‐cigarettes and cigarette cessation outcomes among adults with substance use problems: Results from 2013–2021 (Waves 1–6) of the Population Assessment of Tobacco and Health47
Rare but relevant series45
Naloxone administration—no balance without titration44
How substance use prevention research gets used in United States federal policy44
Response to Hall et al.: Prescription psychostimulants for amphetamine‐type stimulant use disorder ‐ acknowledging challenges but not giving up on its potential cost‐effectiveness42
Commentary on Stull et al.: Considering person‐specific heterogeneity when modeling time‐varying trends41
Quantifying alcohol‐attributable disability‐adjusted life years to others than the drinker in Aotearoa/New Zealand: A modelling study based on administrative data39
Cost‐effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO‐HCV trial39
Did the under‐reporting of meth/amphetamine use increase in a general population survey in Australia as negative media coverage increased?37
Assessing the impacts of alcohol outlets on crime as a natural experiment: agglomeration, churning and spatial effects36
Nicotine strength of e‐liquids used by adult vapers in Great Britain: A population survey 2016 to 202435
Risk of readmission among individuals with cannabis use disorder during a 15‐year cohort study: the impact of socio‐economic factors and psychiatric comorbidity34
Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data34
0.22279500961304